{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:09:36Z","timestamp":1793722176242,"version":"4.6.1"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to explore the clinical efficacy and safety of durvalumab\ncombined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for resectable\nstage III Non-small Cell Lung Cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A single-arm open-label phase Ib study was conducted. A total of 40 patients with driver\ngene-negative resectable stage III NSCLC were enrolled. All patients received neoadjuvant\ntreatment with durvalumab in combination with albumin-bound paclitaxel and carboplatin. The\nclinical efficacy, Major Pathological Response (MPR), Complete Pathological Response (pCR),\nand safety were assessed. Flow cytometry was used to detect the expression of programmed cell\ndeath receptor 1 (PD-1) on total T, helper T, and cytotoxic T lymphocytes in peripheral blood before\nand after neoadjuvant treatment. Adverse reactions during the treatment were recorded. Disease-\nfree Survival (DFS) and Overall Survival (OS) curves were constructed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>After the neoadjuvant treatment, the overall Objective Response Rate (ORR) in the 40 patients\nwith NSCLC was 65.00%. MPR was achieved in 27 patients (67.50%), and pCR was\nachieved in nine patients (22.50%). The expression levels of PD-1 on total T, helper T, and cytotoxic\nT lymphocytes in patients with NSCLC significantly decreased after treatment (all p &lt; 0.05).\nThe most common adverse events were hair loss (47.50%), nausea and vomiting (42.50%), and fatigue\n(40.00%). The majority of adverse events were grades 1 and 2, with a small number of\nevents being grades 3 and 4. At the end of the follow-up period, the average DFS was 21.49 \u00b1\n0.99 months, and the average OS was 24.79 \u00b1 0.53 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel\nand carboplatin as first-line therapy for driver gene-negative stage III NSCLC achieved a high\npathological response rate and improved immune function. It is expected to extend patient survival\nwith good tolerability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115748928304000240429120252","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T04:27:06Z","timestamp":1736310426000},"page":"648-654","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Single-arm, Open-label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer"],"prefix":"10.2174","volume":"20","author":[{"given":"Yuejiao","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The AffiliatedCancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Affiliated Tumor Hospital of Nantong University, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshi","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangsu CancerHospital &amp; Jiangsu Institute of Cancer Research &amp; the Affiliated Cancer Hospital of Nanjing Medical University,Nanjing, Jiangsu, 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninglei","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Jiangsu Cancer Hospital &amp; Jiangsu Institute ofCancer Research &amp; the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The AffiliatedCancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Jiangsu Cancer Hospital &amp; Jiangsu Institute ofCancer Research &amp; the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, the Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated CancerHospital of Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The AffiliatedCancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.21037\/tlcr.2019.03.03","volume":"8","author":"Shankar A.","year":"2019","unstructured":"Shankar A.; Saini D.; Dubey A.; Roy S.; Bharati S.J.; Singh N.; Khanna M.; Prasad C.P.; Singh M.; Kumar S.; Sirohi B.; Seth T.; Rinki M.; Mohan A.; Guleria R.; Rath G.K.; Feasibility of lung cancer screening in developing countries: Challenges, opportunities and way forward. Transl Lung Cancer Res  2019,8(S1),S106-S121","journal-title":"Transl Lung Cancer Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"Ettinger D.S.","year":"2022","unstructured":"Ettinger D.S.; Wood D.E.; Aisner D.L.; Akerley W.; Bauman J.R.; Bharat A.; Bruno D.S.; Chang J.Y.; Chirieac L.R.; D\u2019Amico T.A.; DeCamp M.; Dilling T.J.; Dowell J.; Gettinger S.; Grotz T.E.; Gubens M.A.; Hegde A.; Lackner R.P.; Lanuti M.; Lin J.; Loo B.W.; Lovly C.M.; Maldonado F.; Massarelli E.; Morgensztern D.; Ng T.; Otterson G.A.; Pacheco J.M.; Patel S.P.; Riely G.J.; Riess J.; Schild S.E.; Shapiro T.A.; Singh A.P.; Stevenson J.; Tam A.; Tanvetyanon T.; Yanagawa J.; Yang S.C.; Yau E.; Gregory K.; Hughes M.; Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw  2022,20(5),497-530","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"Chen P.","year":"2022","unstructured":"Chen P.; Liu Y.; Wen Y.; Zhou C.; Non-small cell lung cancer in China. Cancer Commun  2022,42(10),937-970","journal-title":"Cancer Commun"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/07357907.2022.2119479","volume":"41","author":"Abu Rous F.","year":"2023","unstructured":"Abu Rous F.; Singhi E.K.; Sridhar A.; Faisal M.S.; Desai A.; Lung cancer treatment advances in 2022. Cancer Invest  2023,41(1),12-24","journal-title":"Cancer Invest"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","volume":"198","author":"Alexander M.","year":"2020","unstructured":"Alexander M.; Kim S.Y.; Cheng H.; Update 2020: Management of non-small cell lung cancer. Lung  2020,198(6),897-907","journal-title":"Lung"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"Duma N.","year":"2019","unstructured":"Duma N.; Santana-Davila R.; Molina J.R.; Non\u2013small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc  2019,94(8),1623-1640","journal-title":"Mayo Clin Proc"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jtho.2023.07.006","volume":"18","author":"Lee J.M.","year":"2023","unstructured":"Lee J.M.; McNamee C.J.; Toloza E.; Negrao M.V.; Lin J.; Shum E.; Cummings A.L.; Kris M.G.; Sepesi B.; Bara I.; Kurtsikidze N.; Schulze K.; Ngiam C.; Chaft J.E.; Neoadjuvant targeted therapy in resectable NSCLC: Current and future perspectives. J Thorac Oncol  2023,18(11),1458-1477","journal-title":"J Thorac Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"103144","DOI":"10.1016\/j.critrevonc.2020.103144","volume":"157","author":"Jazieh A.R.","year":"2021","unstructured":"Jazieh A.R.; Zeitouni M.; Alghamdi M.; Alrujaib M.; Lotfi S.; Abu Daff S.; Alomair A.; Alshehri S.; Alhusaini H.; Allehebi A.; Ansari J.; Alnassar M.; Jafar H.; Alfarsi A.; Abdelhafeez N.; Alkattan K.; Management guidelines for stage III non-small cell lung cancer. Crit Rev Oncol Hematol  2021,157,103144","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"Doroshow D.B.","year":"2019","unstructured":"Doroshow D.B.; Sanmamed M.F.; Hastings K.; Politi K.; Rimm D.L.; Chen L.; Melero I.; Schalper K.A.; Herbst R.S.; Immunotherapy in non\u2013small cell lung cancer: Facts and hopes. Clin Cancer Res  2019,25(15),4592-4602","journal-title":"Clin Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","volume":"13","author":"Chen Y.","year":"2020","unstructured":"Chen Y.; Gao M.; Huang Z.; Yu J.; Meng X.; SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: A focus on the mechanisms, advances, and future challenges. J Hematol Oncol  2020,13(1),105","journal-title":"J Hematol Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/cam4.3718","volume":"10","author":"Geng Y.","year":"2021","unstructured":"Geng Y.; Zhang Q.; Feng S.; Li C.; Wang L.; Zhao X.; Yang Z.; Li Z.; Luo H.; Liu R.; Lu B.; Wang X.; Safety and efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: A systematic review and meta-analysis. Cancer Med  2021,10(4),1222-1239","journal-title":"Cancer Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.21.00276","volume":"39","author":"Rothschild S.I.","year":"2021","unstructured":"Rothschild S.I.; Zippelius A.; Eboulet E.I.; Prince S.S.; Betticher D.; Bettini A.; Fr\u00fch M.; Joerger M.; Lardinois D.; Gelpke H.; Mauti L.A.; Britschgi C.; Weder W.; Peters S.; Mark M.; Cathomas R.; Ochsenbein A.F.; Janthur W.D.; Waibel C.; Mach N.; Froesch P.; Buess M.; Bohanes P.; Godar G.; Rusterholz C.; Gonzalez M.; Pless M.; SAKK 16\/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non\u2013small-cell lung cancer\u2014A multicenter single-arm phase II trial. J Clin Oncol  2021,39(26),2872-2880","journal-title":"J Clin Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","volume":"21","author":"Shu C.A.","year":"2020","unstructured":"Shu C.A.; Gainor J.F.; Awad M.M.; Chiuzan C.; Grigg C.M.; Pabani A.; Garofano R.F.; Stoopler M.B.; Cheng S.K.; White A.; Lanuti M.; D\u2019Ovidio F.; Bacchetta M.; Sonett J.R.; Saqi A.; Rizvi N.A.; Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol  2020,21(6),786-795","journal-title":"Lancet Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","volume":"18","author":"Girard N.","year":"2023","unstructured":"Girard N.; Bar J.; Garrido P.; Garassino M.C.; McDonald F.; Mornex F.; Filippi A.R.; Smit H.J.M.; Peters S.; Field J.K.; Christoph D.C.; Sibille A.; Fietkau R.; Haakensen V.D.; Chouaid C.; Markman B.; Hiltermann T.J.N.; Taus A.; Sawyer W.; Allen A.; Chander P.; Licour M.; Solomon B.; Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: Findings from the PACIFIC-R study. J Thorac Oncol  2023,18(2),181-193","journal-title":"J Thorac Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"Antonia S.J.","year":"2018","unstructured":"Antonia S.J.; Villegas A.; Daniel D.; Vicente D.; Murakami S.; Hui R.; Kurata T.; Chiappori A.; Lee K.H.; de Wit M.; Cho B.C.; Bourhaba M.; Quantin X.; Tokito T.; Mekhail T.; Planchard D.; Kim Y.C.; Karapetis C.S.; Hiret S.; Ostoros G.; Kubota K.; Gray J.E.; Paz-Ares L.; de Carpe\u00f1o C.J.; Finn F.C.; Reck M.; Vansteenkiste J.; Spigel D.R.; Wadsworth C.; Melillo G.; Taboada M.; Dennis P.A.; \u00d6zg\u00fcro\u011flu M.; Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med  2018,379(24),2342-2350","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/14712598.2019.1635115","volume":"19","author":"Argote A.J.","year":"2019","unstructured":"Argote A.J.; Dasanu C.A.; Durvalumab in cancer medicine: A comprehensive review. Expert Opin Biol Ther  2019,19(9),927-935","journal-title":"Expert Opin Biol Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cllc.2023.01.008","volume":"24","author":"Miyanaga A.","year":"2023","unstructured":"Miyanaga A.; Asahina H.; Watanabe S.; Shukuya T.; Tsubata Y.; Hosomi Y.; Sugawara S.; Maemondo M.; Okano T.; Morita S.; Matsuyama K.; Kobayashi K.; Seike M.; A phase I\/II study of necitumumab plus pembrolizumab, nab-paclitaxel, and carboplatin for previously untreated advanced squamous non\u2013small cell lung cancer study: (NEJ048A\/NEXUS). Clin Lung Cancer  2023,24(4),371-375","journal-title":"Clin Lung Cancer"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1111\/1759-7714.14664","volume":"13","author":"Chai Y.","year":"2022","unstructured":"Chai Y.; Wu X.; Zou Y.; Zhang X.; Bai H.; Dong M.; Duan J.; Immunotherapy combined with chemotherapy versus chemotherapy alone as the first-line treatment of -negative and driver-gene-negative advanced nonsquamous non-small-cell lung cancer: An updated systematic review and meta-analysis. Thorac Cancer  2022,13(22),3124-3132","journal-title":"Thorac Cancer"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"Eisenhauer E.A.","year":"2009","unstructured":"Eisenhauer E.A.; Therasse P.; Bogaerts J.; Schwartz L.H.; Sargent D.; Ford R.; Dancey J.; Arbuck S.; Gwyther S.; Mooney M.; Rubinstein L.; Shankar L.; Dodd L.; Kaplan R.; Lacombe D.; Verweij J.; New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer  2009,45(2),228-247","journal-title":"Eur J Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"Hellmann M.D.","year":"2014","unstructured":"Hellmann M.D.; Chaft J.E.; William W.N.; Rusch V.; Pisters K.M.W.; Kalhor N.; Pataer A.; Travis W.D.; Swisher S.G.; Kris M.G.; Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: Proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol  2014,15(1),e42-e50","journal-title":"Lancet Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"Travis W.D.","year":"2020","unstructured":"Travis W.D.; Dacic S.; Wistuba I.; Sholl L.; Adusumilli P.; Bubendorf L.; Bunn P.; Cascone T.; Chaft J.; Chen G.; Chou T.Y.; Cooper W.; Erasmus J.J.; Ferreira C.G.; Goo J.M.; Heymach J.; Hirsch F.R.; Horinouchi H.; Kerr K.; Kris M.; Jain D.; Kim Y.T.; Lopez-Rios F.; Lu S.; Mitsudomi T.; Moreira A.; Motoi N.; Nicholson A.G.; Oliveira R.; Papotti M.; Pastorino U.; Paz-Ares L.; Pelosi G.; Poleri C.; Provencio M.; Roden A.C.; Scagliotti G.; Swisher S.G.; Thunnissen E.; Tsao M.S.; Vansteenkiste J.; Weder W.; Yatabe Y.; IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol  2020,15(5),709-740","journal-title":"J Thorac Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1080\/14737140.2023.2272645","volume":"23","author":"Ostoros G.","year":"2023","unstructured":"Ostoros G.; Hettle R.; Georgoulia N.; Berktas M.; Chander P.; Perez D.I.; Couto A.M.; Eichinger C.; Field P.; Morten P.; Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: A systematic review and meta-analysis. Expert Rev Anticancer Ther  2023,23(12),1305-1313","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMc1900407","volume":"380","author":"Kim Y.H.","year":"2019","unstructured":"Kim Y.H.; Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med  2019,380(10),989-990","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s11136-023-03424-y","volume":"32","author":"Matsuda A.","year":"2023","unstructured":"Matsuda A.; Yamaoka K.; Kunitoh H.; Seto T.; Tsuboi M.; Ohira T.; Maruyama R.; Okamoto H.; Kubota K.; Quality of life with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: quality of life analysis of TORG 0503. Qual Life Res  2023,32(9),2629-2637","journal-title":"Qual Life Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1166\/jnn.2020.18880","volume":"20","author":"Wang H.","year":"2020","unstructured":"Wang H.; Mou S.; Tu M.; Study on the effect of nano albumin paclitaxel combined with carboplatin in the treatment of lung squamous cell carcinoma. J Nanosci Nanotechnol  2020,20(12),7439-7443","journal-title":"J Nanosci Nanotechnol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"17588359211029826","DOI":"10.1177\/17588359211029826","volume":"13","author":"Gan J.","year":"2021","unstructured":"Gan J.; Huang Y.; Fang W.; Zhang L.; Research progress in immune checkpoint inhibitors for lung cancer in China. Ther Adv Med Oncol  2021,13,17588359211029826","journal-title":"Ther Adv Med Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.21037\/atm-21-670","volume":"9","author":"Wang J.","year":"2021","unstructured":"Wang J.; Li J.; Cai L.; Chen S.; Jiang Y.; The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer. Ann Transl Med  2021,9(6),486","journal-title":"Ann Transl Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/cncr.34930","volume":"129","author":"Patel S.A.","year":"2023","unstructured":"Patel S.A.; Gibson M.K.; Deal A.; Sheth S.; Heiling H.; Johnson S.M.; Douglas K.; Flores M.; Blumberg J.; Lumley C.; Yarbrough W.G.; Shen C.; Chera B.S.; Bauman J.R.; Hackman T.; Weiss J.; A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma. Cancer  2023,129(21),3381-3389","journal-title":"Cancer"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","volume":"21","author":"Provencio M.","year":"2020","unstructured":"Provencio M.; Nadal E.; Insa A.; Campelo G.M.R.; Rubio C.J.; D\u00f3mine M.; Majem M.; Abreu R.D.; Mart\u00ed M.A.; De Carpe\u00f1o C.J.; Cobo M.; Vivanco L.G.; Barco D.E.; Caro B.R.; Vi\u00f1olas N.; Aranda B.I.; Viteri S.; Pereira E.; Royuela A.; Casarrubios M.; Ant\u00f3n S.C.; Parra E.R.; Wistuba I.; Calvo V.; Briviesca L.R.; Romero A.; Massuti B.; Berm\u00fadez C.A.; Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol  2020,21(11),1413-1422","journal-title":"Lancet Oncol"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928304000240429120252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238095\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928304000240429120252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T05:51:03Z","timestamp":1764568263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238095\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748928304000240429120252","relation":{},"ISSN":["1574-8928"],"issn-type":[{"value":"1574-8928","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}